Similarly, patients with non-metastatic breast cancer positive for human epidermal growth factor receptor-2 have a greater than 40% reduction in recurrence risk with targeted therapies such as trastuzumab or biosimilars, which are becoming increasingly available in low- and middle-income country markets.4 The gene discussed is ERBB2; the disease is breast carcinoma.